Cargando…
Ablation Therapy for Persistent Atrial Fibrillation
Atrial Fibrillation (AF) is the most common form of electrical disturbance of the heart and contributes to significant patient morbidity and mortality. With a better understanding of the mechanisms of atrial fibrillation and improvements in mapping and ablation technologies, ablation has become a pr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413731/ https://www.ncbi.nlm.nih.gov/pubmed/34325644 http://dx.doi.org/10.2174/1573403X17666210729101752 |
_version_ | 1784775821299286016 |
---|---|
author | Ifedili, Ikechukwu Mouksian, Kristina Jones, David El Masri, Ibrahim Heckle, Mark Jefferies, John Levine, Yehoshua C. |
author_facet | Ifedili, Ikechukwu Mouksian, Kristina Jones, David El Masri, Ibrahim Heckle, Mark Jefferies, John Levine, Yehoshua C. |
author_sort | Ifedili, Ikechukwu |
collection | PubMed |
description | Atrial Fibrillation (AF) is the most common form of electrical disturbance of the heart and contributes to significant patient morbidity and mortality. With a better understanding of the mechanisms of atrial fibrillation and improvements in mapping and ablation technologies, ablation has become a preferred therapy for patients with symptomatic AF. Pulmonary Vein Isolation (PVI) is the cornerstone for AF ablation therapy, but particularly in patients with AF occurring for longer than 7 days (persistent AF), identifying clinically significant nonpulmonary vein targets and achieving durability of ablation lesions remains an important challenge. |
format | Online Article Text |
id | pubmed-9413731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-94137312023-03-18 Ablation Therapy for Persistent Atrial Fibrillation Ifedili, Ikechukwu Mouksian, Kristina Jones, David El Masri, Ibrahim Heckle, Mark Jefferies, John Levine, Yehoshua C. Curr Cardiol Rev Article Atrial Fibrillation (AF) is the most common form of electrical disturbance of the heart and contributes to significant patient morbidity and mortality. With a better understanding of the mechanisms of atrial fibrillation and improvements in mapping and ablation technologies, ablation has become a preferred therapy for patients with symptomatic AF. Pulmonary Vein Isolation (PVI) is the cornerstone for AF ablation therapy, but particularly in patients with AF occurring for longer than 7 days (persistent AF), identifying clinically significant nonpulmonary vein targets and achieving durability of ablation lesions remains an important challenge. Bentham Science Publishers 2022-03-18 2022-03-18 /pmc/articles/PMC9413731/ /pubmed/34325644 http://dx.doi.org/10.2174/1573403X17666210729101752 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Ifedili, Ikechukwu Mouksian, Kristina Jones, David El Masri, Ibrahim Heckle, Mark Jefferies, John Levine, Yehoshua C. Ablation Therapy for Persistent Atrial Fibrillation |
title | Ablation Therapy for Persistent Atrial Fibrillation |
title_full | Ablation Therapy for Persistent Atrial Fibrillation |
title_fullStr | Ablation Therapy for Persistent Atrial Fibrillation |
title_full_unstemmed | Ablation Therapy for Persistent Atrial Fibrillation |
title_short | Ablation Therapy for Persistent Atrial Fibrillation |
title_sort | ablation therapy for persistent atrial fibrillation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413731/ https://www.ncbi.nlm.nih.gov/pubmed/34325644 http://dx.doi.org/10.2174/1573403X17666210729101752 |
work_keys_str_mv | AT ifediliikechukwu ablationtherapyforpersistentatrialfibrillation AT mouksiankristina ablationtherapyforpersistentatrialfibrillation AT jonesdavid ablationtherapyforpersistentatrialfibrillation AT elmasriibrahim ablationtherapyforpersistentatrialfibrillation AT hecklemark ablationtherapyforpersistentatrialfibrillation AT jefferiesjohn ablationtherapyforpersistentatrialfibrillation AT levineyehoshuac ablationtherapyforpersistentatrialfibrillation |